1 Department of Clinical Neurosciences, University of Cambridge, UK 2 Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK
1 Department of Clinical Neurosciences, University of Cambridge, UK.
Brain. 2015 Jul;138(Pt 7):1961-75. doi: 10.1093/brain/awv133. Epub 2015 May 21.
Disinhibition is a cardinal feature of the behavioural variant of frontotemporal dementia, presenting as impulsive and impetuous behaviours that are often difficult to manage. The options for symptomatic treatments are limited, but a potential target for therapy is the restoration of serotonergic function, which is both deficient in behavioural variant frontotemporal dementia and closely associated with inhibitory control. Based on preclinical studies and psychopharmacological interventions in other disorders, we predicted that inhibition would be associated with the right inferior frontal gyrus and dependent on serotonin. Using magnetoencephalography and electroencephalography of a Go-NoGo paradigm, we investigated the neural basis of behavioural disinhibition in behavioural variant frontotemporal dementia and the effect of selective serotonin reuptake inhibition on the neural systems for response inhibition. In a randomized double-blinded placebo-controlled crossover design study, 12 patients received either a single 30 mg dose of citalopram or placebo. Twenty age-matched healthy controls underwent the same magnetoencephalography/electroencephalography protocol on one session without citalopram, providing normative data for this task. In the control group, successful NoGo trials evoked two established indices of successful response inhibition: the NoGo-N2 and NoGo-P3. Both of these components were significantly attenuated by behavioural variant frontotemporal dementia. Cortical sources associated with successful inhibition in control subjects were identified in the right inferior frontal gyrus and anterior temporal lobe, which have been strongly associated with behavioural inhibition in imaging and lesion studies. These sources were impaired by behavioural variant frontotemporal dementia. Critically, citalopram enhanced the NoGo-P3 signal in patients, relative to placebo treatment, and increased the evoked response in the right inferior frontal gyrus. Voxel-based morphometry confirmed significant atrophy of inferior frontal gyrus, alongside insular, orbitofrontal and temporal cortex in our patient cohort. Together, these data suggest that the dysfunctional prefrontal cortical systems underlying response inhibition deficits in behavioural variant frontotemporal dementia can be partially restored by increasing serotonergic neurotransmission. The results support a translational neuroscience approach to impulsive neurological disorders and indicate the potential for symptomatic treatment of behavioural variant frontotemporal dementia including serotonergic strategies to improve disinhibition.media-1vid110.1093/brain/awv133_video_abstractawv133_video_abstract.
抑制障碍是额颞叶痴呆行为变异型的主要特征,表现为冲动和鲁莽的行为,往往难以控制。对症治疗的选择有限,但治疗的潜在靶点是恢复 5-羟色胺能功能,这在行为变异型额颞叶痴呆中既缺乏,又与抑制控制密切相关。基于临床前研究和其他疾病的精神药理学干预,我们预测抑制将与右侧额下回有关,并依赖于 5-羟色胺。我们使用 Go-NoGo 范式的脑磁图和脑电图来研究行为变异型额颞叶痴呆中行为抑制障碍的神经基础,以及选择性 5-羟色胺再摄取抑制对反应抑制神经系统的影响。在一项随机、双盲、安慰剂对照的交叉设计研究中,12 名患者接受了单次 30mg 西酞普兰或安慰剂治疗。20 名年龄匹配的健康对照者在一次无西酞普兰的会话中接受了相同的脑磁图/脑电图方案,为该任务提供了规范数据。在对照组中,成功的 NoGo 试验引起了两个成功的反应抑制的既定指标:NoGo-N2 和 NoGo-P3。这两个成分在行为变异型额颞叶痴呆中均显著减弱。在控制组中,与成功抑制相关的皮质源被确定在右侧额下回和前颞叶,这在成像和病变研究中与行为抑制强烈相关。这些来源在行为变异型额颞叶痴呆中受到损害。关键的是,与安慰剂治疗相比,西酞普兰增强了患者的 NoGo-P3 信号,并增加了右侧额下回的诱发反应。基于体素的形态测量学证实,我们的患者队列中存在额下回、岛叶、眶额和颞叶皮质的显著萎缩。总之,这些数据表明,行为变异型额颞叶痴呆中反应抑制缺陷的功能失调的前额叶皮质系统可以通过增加 5-羟色胺能神经传递来部分恢复。结果支持冲动性神经障碍的转化神经科学方法,并表明包括改善抑制障碍的 5-羟色胺策略在内的行为变异型额颞叶痴呆的对症治疗的潜力。